GSC showed enhanced antitumor activity based on the results of cell proliferation and clonogenic potential in multiple KRAS-mutated colorectal cancer cells such as SW480 (KRASG12V), LS513 (KRASG12D) and HCT116 (KRASG13D) (Figure 1). The gene discussed is KRAS; the disease is colorectal cancer.